Find disease awareness content and relevant supporting materials
The New Heart Failure Association Definition of Advanced Heart Failure
The clinical course of heart failure is characterised by progressive worsening of cardiac function and symptoms. Patients progress to a condition where traditional treatment is no longer effective and advanced therapies...
Efficacy and safety of intermittent intravenous outpatient administration of levosimendan in patients with advanced heart failure: the LION-HEART multicentre randomised trial.
Aims: The LION-HEART study was a multicentre, double-blind, randomised, parallel-group, placebo-controlled trial evaluating the efficacy and safety of intravenous administration of intermittent doses of levosimendan in outpatients with advanced chronic heart failure.
Haemodynamic effects of levosimendan in advanced but stable chronic heart failure
Aims: Levosimendan improves haemodynamics in acute decompensated heart failure (HF). However, it is increasingly used for repetitive or intermittent infusions in advanced but stable chronic HF, without clear indication...
Additional analyses from phase III GALACTIC-HF study of AMG 423 showed impact in atrial fibrillation.- Cytokinetics
Cytokinetics announced that additional results from the phase III GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure) of AMG 423 (omecamtiv mecarbil), including a prespecified subgroup analysis of the influence of atrial fibrillation or flutter (AFF) on the treatment effect of omecamtiv mecarbil in a Late Breaking Clinical Trial Session.
Heartmate 3 fully magnetically levitated left ventricular assist device for the treatment of advanced heart failure - 1 year results from the CE Mark trial.
The HeartMate 3 Left Ventricular Assist System (LVAS) (St. Jude Medical Inc., St Paul, MN) with full magnetic levitation allows for wide and consistent blood flow paths and an artificial pulse designed for enhanced hemocompatibility.